// Real-Time Intelligence Feed

Financial Intelligence.
Real-Time.

SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.

18,989
Stories Indexed
Live
Feed Status
6
Data Sources
AllEarningsFDAM&AInsider TradingRegulatoryOfferingLeadershipRestructuringDividendInstitutional HoldingsBankruptcy
ALL STORIES · 18,989 results Live
FDA Hikma Aug 29 — 0.00

FDA Approves VIGABATRIN — Hikma Pharmaceuticals USA Inc

Hikma Pharmaceuticals USA Inc. received FDA approval for its generic oral version of Vigabatrin in August, a move expected to bolster the company's anticonvulsant portfolio and dri…

FDA Axsome Aug 18 — 0.00

FDA Approves AUVELITY — Axsome Therapeutics, Inc.

# FDA Approves Axsome Therapeutics' AUVELITY for Major Depressive Disorder Axsome Therapeutics received FDA approval for AUVELITY (dextromethorphan hydrobromide/bupropion hydrochl…

News SYTA · SYTAW · T Aug 4 — 0.00

Building Distribution: Is Siyata's Group Of Strategic Business Collaborators Ready To Impact The Push-To-Talk Market?

Building Distribution: Is Siyata's Group Of Strategic Business Collaborators Ready To Impact The Push-To-Talk Market?

FDA AstraZeneca Aug 3 — 0.00

FDA Approves CALQUENCE — AstraZeneca Pharmaceuticals LP

# FDA Approves AstraZeneca's CALQUENCE (acalabrutinib) AstraZeneca Pharmaceuticals LP received FDA approval for CALQUENCE (acalabrutinib), an oral Bruton's tyrosine kinase inhibi…

Penny Stocks AAPL · SONM · SYTA Jun 22 — 0.00

Is Siyata Mobile Walkie-ing The Talk-ie? Connecting People Around The World Via Next-Gen Mission-Critical Devices

Is Siyata Mobile Walkie-ing The Talk-ie? Connecting People Around The World Via Next-Gen Mission-Critical Devices

FDA AbbVie Jun 16 — 0.00

FDA Approves SKYRIZI — AbbVie Inc.

AbbVie announced the FDA approval of risankizumab-RZAA (Skyrizi) for intravenous use, a formulation that may broaden the biologic’s market presence alongside its current subcutaneo…

Penny Stocks SYTA · T · VZ Jun 15 — 0.00

Are New Communication Products Like The SD7 Poised To Give A Significant Boost To The Push-To-Talk Market?

Are New Communication Products Like The SD7 Poised To Give A Significant Boost To The Push-To-Talk Market?

FDA Eugia Jun 6 — 0.00

FDA Approves LEUPROLIDE ACETATE — Eugia US LLC

# FDA Approves Eugia US LLC's Generic Leuprolide Acetate Eugia US LLC received FDA approval for its generic leuprolide acetate formulation, marking another entry into the competit…

FDA Aurobindo May 10 — 0.00

FDA Approves VIGABATRIN — Aurobindo Pharma Limited

# FDA Approves Aurobindo Pharma's Generic Vigabatrin, Expanding Treatment Options for Seizure Disorders The FDA has approved Aurobindo Pharma Limited's generic formulation of viga…

FDA Teva May 4 — 0.00

FDA Approves POMALIDOMIDE — Teva Pharmaceuticals, Inc.

# FDA Approves Generic Version of Pomalidomide; Teva Gains Market Entry Teva Pharmaceuticals, Inc. received FDA approval for its generic oral pomalidomide formulation (ANDA209956)…

FDA LUPIN May 3 — 0.00

FDA Approves Unknown Drug — LUPIN LTD

# FDA Approves Lupin Ltd's Generic Drug Application Lupin Ltd has received FDA approval for generic drug application ANDA091040, expanding the company's portfolio in the competiti…

FDA Solco Apr 7 — 0.00

FDA Approves NEBIVOLOL — Solco Healthcare US, LLC

# FDA Approves Generic Nebivolol; Solco Healthcare Entry Expected to Intensify Competition in Beta-Blocker Market Solco Healthcare US, LLC received FDA approval for generic nebivo…

FDA Novartis Mar 23 — 0.00

FDA Approves PLUVICTO — Novartis Pharmaceuticals Corporation

# FDA Approves Novartis's PLUVICTO for Prostate Cancer Treatment Novartis Pharmaceuticals Corporation received FDA approval for PLUVICTO (lutetium lu-177 vipivotide tetraxetan), a…

FDA Eskayef Mar 8 — 0.00

FDA Approves PREGABALIN — Eskayef Pharmaceuticals Limited

# FDA Approves Pregabalin Generic from Eskayef Pharmaceuticals Eskayef Pharmaceuticals Limited received FDA approval for its generic pregabalin oral formulation (ANDA212988), addi…

FDA Sobi, Feb 28 — 0.00

FDA Approves VONJO — Sobi, Inc.

Sobi, Inc. received FDA approval for VONJO (pacritinib) to treat adult patients with Philadelphia-negative myelofibrosis who have intolerant or refractory to ruxolitinib, a develop…

FDA BluePoint Feb 25 — 0.00

FDA Approves DIVALPROEX SODIUM — BluePoint Laboratories

# FDA Approves Generic Divalproex Sodium for BluePoint Laboratories BluePoint Laboratories has received FDA approval for its generic divalproex sodium oral formulation, expanding …

FDA Apotex Jan 31 — 0.00

FDA Approves BRIMONIDINE TARTRATE — Apotex Corp.

# FDA Approves Apotex's Generic Brimonidine Tartrate Ophthalmic Treatment Apotex Corp. received FDA approval for its generic brimonidine tartrate ophthalmic formulation, expanding…

FDA Genentech, Jan 28 — 0.00

FDA Approves VABYSMO — Genentech, Inc.

# FDA Approves Genentech's VABYSMO for Retinal Disease Treatment Genentech has received FDA approval for VABYSMO (faricimab), a novel intravitreal injection marking the company's …

FDA MYLAN Jan 26 — 0.00

FDA Approves Unknown Drug — MYLAN

# FDA Approval Newswire Mylan received FDA approval for a generic drug application (ANDA210275) on January 26, 2022, positioning the company to capture additional market share in …

FDA Zydus Jan 19 — 0.00

FDA Approves VIGABATRIN — Zydus Pharmaceuticals (USA) Inc.

# FDA Approves Generic Vigabatrin The FDA has approved Zydus Pharmaceuticals' generic version of vigabatrin, an oral antiepileptic medication, potentially expanding market competi…